Tisotumab Vedotin Cervical Cancer Trial Completion
Mar 31, 2026, 4:00:00 AM UTC
Summary
The Phase 1/2 clinical trial evaluating Tisotumab Vedotin, an antibody-drug conjugate, as monotherapy and in combination with other agents for cervical cancer is expected to complete on March 31, 2026. The study, sponsored by Seagen (a Pfizer subsidiary) and involving Genmab (GMAB), assesses safety and efficacy in patients with recurrent or advanced cervical cancer across multiple treatment arms. Tisotumab Vedotin is a targeted therapy designed to deliver cytotoxic agents directly to cancer cells, and is categorized as an oncology biologic.
Company
GENMAB A (GMAB)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.genmab.comSimilar Events
Tisotumab Vedotin Phase 3 Cervical Cancer Trial Completion
A Phase 3 clinical trial evaluating tisotumab vedotin versus physician's choice of chemotherapy in patients with recurrent or metastatic cervical cancer is expected to complete on May 7, 2026. The study, sponsored by Seagen Inc. (a Pfizer subsidiary) and involving 502 participants, aims to determine whether tisotumab vedotin improves outcomes compared to standard chemotherapy options. Tisotumab vedotin is an antibody-drug conjugate targeting tissue factor, developed by Seagen and Genmab (GMAB).
trial completionExpected Trial Completion for Tisotumab Vedotin Study
A Phase 2 clinical trial evaluating tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, in patients with selected solid tumors is expected to complete on August 14, 2026. The study, sponsored by Seagen (a Pfizer subsidiary) and involving Genmab (GMAB), is assessing efficacy, safety, and tolerability in tumor types including colorectal cancer, squamous non-small cell lung cancer, exocrine pancreatic adenocarcinoma, and head and neck squamous cell carcinoma. The trial has enrolled 352 participants and is not currently recruiting.
trial completionClinical Trial Completion for Disitamab Vedotin
The clinical trial evaluating disitamab vedotin in combination with tucatinib is expected to complete on July 28, 2029, focusing on HER2-expressing cancers. This Phase 2 trial, sponsored by Seagen Inc., a subsidiary of Pfizer, aims to assess the safety and efficacy of the combination therapy in patients with locally advanced or metastatic breast and gastric cancers. The trial includes a dose escalation and optimization phase, followed by an expansion phase with multiple cohorts.
trial completionPhase 2 Clinical Trial Completion for Disitamab Vedotin in HER2+ Solid Tumors
A Phase 2 clinical trial evaluating disitamab vedotin, an antibody-drug conjugate (ADC), in patients with advanced or metastatic HER2-expressing solid tumors is expected to complete on May 31, 2028. The study, sponsored by Seagen Inc., a Pfizer subsidiary, targets cancers including head and neck, non-small cell lung, endometrial, and ovarian cancers. The trial aims to assess the efficacy and safety of disitamab vedotin, with 119 participants enrolled.
trial completion